Siemens Healthineers

Siemens Healthineers AG (XETR: SHL) is a medical technology company that designs, develops, produces, and distributes diagnostic imaging systems, clinical and workflow systems and solutions, and systems for minimally invasive procedures. Siemens Healthineers operates in more than 70 countries and is a subsidiary of the Siemens Group (holding over 75% of its shares ). Siemens Healthineers became a publicly listed company in March 2018, with shares officially traded on both the Frankfurt am Main and Xetra stock exchanges. Siemens Healthineers generated revenue of EUR 21.7 billion (USD 23.8 billion) in FY2023 (year ending  September 30).

Siemens Healthineers reports its revenue under four segments. The Imaging segment is the largest (~54% of total revenue in FY2023) and includes solutions related to magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound. The Diagnostics segment encompasses solutions related to immunochemistry, hematology, coagulation, urinalysis, blood gas analysis, and molecular tests. The Varian segment offers advanced and diversified technologies for cancer care and services to oncology departments, while the Advanced Therapies segment provides image-guided services for areas such as cardiology, interventional radiology, and surgery.

The Americas region is Siemens Healthineers’ largest market (~41% total revenue in FY2023), followed by the Europe, Commonwealth of Independent States (CIS), Africa, Middle East (EMEA) region. Siemens Healthineers’ medium-term plan (FY2023–FY2025) expects comparable revenue growth of 6%–8% per annum (-0.2% YoY in FY2023) and margin improvements across all segments. Siemens Healthineers expects to reach net-zero status by 2030.